https://stock.noler.com/us/stock/forward-pharma-a-s https://stock.noler.com/us/stock/forward-pharma-a-s/accounting-profit https://stock.noler.com/us/stock/forward-pharma-a-s/accrued-income https://stock.noler.com/us/stock/forward-pharma-a-s/acquisitiondate-fair-value-of-total-consideration-transferred https://stock.noler.com/us/stock/forward-pharma-a-s/adjusted-weighted-average-shares https://stock.noler.com/us/stock/forward-pharma-a-s/adjustments-for-current-tax-of-prior-period https://stock.noler.com/us/stock/forward-pharma-a-s/adjustments-for-depreciation-and-amortisation-expense-and-impairment-loss-reversal-of-impairment-loss-recognised-in-profit-or-loss https://stock.noler.com/us/stock/forward-pharma-a-s/adjustments-for-depreciation-expense https://stock.noler.com/us/stock/forward-pharma-a-s/adjustments-for-impairment-loss-reversal-of-impairment-loss-recognised-in-profit-or-loss-trade-and-other-receivables https://stock.noler.com/us/stock/forward-pharma-a-s/adjustments-for-increase-decrease-in-trade-account-payable https://stock.noler.com/us/stock/forward-pharma-a-s/adjustments-for-increase-decrease-in-trade-and-other-payables https://stock.noler.com/us/stock/forward-pharma-a-s/adjustments-for-share-based-payments https://stock.noler.com/us/stock/forward-pharma-a-s/amounts-payable-related-party-transactions https://stock.noler.com/us/stock/forward-pharma-a-s/applicable-tax-rate https://stock.noler.com/us/stock/forward-pharma-a-s/average-effective-tax-rate https://stock.noler.com/us/stock/forward-pharma-a-s/average-exercise-price-of-other-equity-instruments-exercisable-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/forward-pharma-a-s/average-exercise-price-of-share-options-exercised-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/forward-pharma-a-s/average-exercise-price-of-share-options-expired-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/forward-pharma-a-s/average-exercise-price-of-share-options-forfeited-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/forward-pharma-a-s/average-exercise-price-of-share-options-granted-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/forward-pharma-a-s/average-exercise-price-of-share-options-outstanding-in-share-based-payment-arrangement-2019 https://stock.noler.com/us/stock/forward-pharma-a-s/basic-and-diluted-earnings-loss-per-share https://stock.noler.com/us/stock/forward-pharma-a-s/basic-earnings-loss-per-share https://stock.noler.com/us/stock/forward-pharma-a-s/capital-commitments https://stock.noler.com/us/stock/forward-pharma-a-s/cash-and-cash-equivalents https://stock.noler.com/us/stock/forward-pharma-a-s/cash-flows-from-used-in-financing-activities https://stock.noler.com/us/stock/forward-pharma-a-s/cash-flows-from-used-in-investing-activities https://stock.noler.com/us/stock/forward-pharma-a-s/cash-flows-from-used-in-operating-activities https://stock.noler.com/us/stock/forward-pharma-a-s/cash-outflow-for-leases https://stock.noler.com/us/stock/forward-pharma-a-s/comprehensive-income https://stock.noler.com/us/stock/forward-pharma-a-s/comprehensive-income-attributable-to-owners-of-parent https://stock.noler.com/us/stock/forward-pharma-a-s/cover-page-shares-outstanding https://stock.noler.com/us/stock/forward-pharma-a-s/current-accrued-expenses-and-other-current-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/current-assets https://stock.noler.com/us/stock/forward-pharma-a-s/current-financial-assets-available-for-sale https://stock.noler.com/us/stock/forward-pharma-a-s/current-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/current-prepaid-expenses https://stock.noler.com/us/stock/forward-pharma-a-s/current-tax-assets-current https://stock.noler.com/us/stock/forward-pharma-a-s/current-tax-expense-income https://stock.noler.com/us/stock/forward-pharma-a-s/current-tax-liabilities-current https://stock.noler.com/us/stock/forward-pharma-a-s/decrease-increase-through-tax-on-share-based-payment-transactions https://stock.noler.com/us/stock/forward-pharma-a-s/deductible-temporary-differences-for-which-no-deferred-tax-asset-is-recognised https://stock.noler.com/us/stock/forward-pharma-a-s/deferred-tax-expense-income-recognised-in-profit-or-loss https://stock.noler.com/us/stock/forward-pharma-a-s/deferred-tax-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/deferred-tax-liability-asset https://stock.noler.com/us/stock/forward-pharma-a-s/depreciation-property-plant-and-equipment https://stock.noler.com/us/stock/forward-pharma-a-s/derivative-financial-assets https://stock.noler.com/us/stock/forward-pharma-a-s/description-of-expected-volatility-share-options-granted https://stock.noler.com/us/stock/forward-pharma-a-s/description-of-option-life-share-options-granted https://stock.noler.com/us/stock/forward-pharma-a-s/description-of-risk-free-interest-rate-share-options-granted https://stock.noler.com/us/stock/forward-pharma-a-s/diluted-earnings-loss-per-share https://stock.noler.com/us/stock/forward-pharma-a-s/dilutive-effect-of-convertible-instruments-on-number-of-ordinary-shares https://stock.noler.com/us/stock/forward-pharma-a-s/effect-of-exchange-rate-changes-on-cash-and-cash-equivalents https://stock.noler.com/us/stock/forward-pharma-a-s/employee-benefits-expense https://stock.noler.com/us/stock/forward-pharma-a-s/equity https://stock.noler.com/us/stock/forward-pharma-a-s/equity-and-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/equity-attributable-to-owners-of-parent https://stock.noler.com/us/stock/forward-pharma-a-s/estimated-financial-effect-of-contingent-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/exercise-price-share-options-granted-2019 https://stock.noler.com/us/stock/forward-pharma-a-s/expected-dividend-as-percentage-share-options-granted https://stock.noler.com/us/stock/forward-pharma-a-s/expense-from-equitysettled-share-based-payment-transactions-in-which-goods-or-services-received-did-not-qualify-for-recognition-as-assets https://stock.noler.com/us/stock/forward-pharma-a-s/expense-from-share-based-payment-transactions-with-employees https://stock.noler.com/us/stock/forward-pharma-a-s/foreign-exchange-gain https://stock.noler.com/us/stock/forward-pharma-a-s/foreign-exchange-loss https://stock.noler.com/us/stock/forward-pharma-a-s/gains-losses-on-exchange-differences-on-translation-recognised-in-profit-or-loss https://stock.noler.com/us/stock/forward-pharma-a-s/general-and-administrative-expense https://stock.noler.com/us/stock/forward-pharma-a-s/impairment-loss https://stock.noler.com/us/stock/forward-pharma-a-s/income-tax-expense https://stock.noler.com/us/stock/forward-pharma-a-s/income-taxes-paid-classified-as-operating-activities https://stock.noler.com/us/stock/forward-pharma-a-s/income-taxes-paid-refund-classified-as-operating-activities https://stock.noler.com/us/stock/forward-pharma-a-s/income-taxes-refund-classified-as-operating-activities https://stock.noler.com/us/stock/forward-pharma-a-s/increase-decrease-in-cash-and-cash-equivalents-before-effect-of-exchange-rate-changes https://stock.noler.com/us/stock/forward-pharma-a-s/increase-decrease-through-exercise-of-warrants-equity https://stock.noler.com/us/stock/forward-pharma-a-s/increase-decrease-through-share-based-payment-transactions https://stock.noler.com/us/stock/forward-pharma-a-s/increase-decrease-through-transactions-with-owners https://stock.noler.com/us/stock/forward-pharma-a-s/interest-expense https://stock.noler.com/us/stock/forward-pharma-a-s/interest-income-on-available-for-sale-financial-assets https://stock.noler.com/us/stock/forward-pharma-a-s/interest-received-classified-as-operating-activities https://stock.noler.com/us/stock/forward-pharma-a-s/issued-capital https://stock.noler.com/us/stock/forward-pharma-a-s/key-management-personnel-compensation https://stock.noler.com/us/stock/forward-pharma-a-s/key-management-personnel-compensation-share-based-payment https://stock.noler.com/us/stock/forward-pharma-a-s/key-management-personnel-compensation-shortterm-employee-benefits https://stock.noler.com/us/stock/forward-pharma-a-s/minimum-lease-payments-payable-under-noncancellable-operating-lease https://stock.noler.com/us/stock/forward-pharma-a-s/minimum-operating-lease-payments https://stock.noler.com/us/stock/forward-pharma-a-s/net-deferred-tax-assets https://stock.noler.com/us/stock/forward-pharma-a-s/net-deferred-tax-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/net-foreign-exchange-gain https://stock.noler.com/us/stock/forward-pharma-a-s/net-foreign-exchange-loss https://stock.noler.com/us/stock/forward-pharma-a-s/noncurrent-assets https://stock.noler.com/us/stock/forward-pharma-a-s/noncurrent-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-instruments-granted-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-instruments-other-equity-instruments-granted https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-other-equity-instruments-exercisable-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-other-equity-instruments-exercised-or-vested-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-other-equity-instruments-expired-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-other-equity-instruments-forfeited-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-other-equity-instruments-outstanding-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-outstanding-share-options https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-share-options-exercisable-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-share-options-exercised-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-share-options-expired-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-share-options-forfeited-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-share-options-granted-in-share-based-payment-arrangement https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-shares-issued https://stock.noler.com/us/stock/forward-pharma-a-s/number-of-shares-outstanding https://stock.noler.com/us/stock/forward-pharma-a-s/oci-net-of-tax-available-for-sale-financial-assets https://stock.noler.com/us/stock/forward-pharma-a-s/oci-net-of-tax-exchange-differences-on-translation https://stock.noler.com/us/stock/forward-pharma-a-s/oci-net-of-tax-exchange-differences-on-translation-other-than-translation-of-foreign-operations https://stock.noler.com/us/stock/forward-pharma-a-s/oci-that-will-be-reclassified-to-profit-or-loss-net-of-tax https://stock.noler.com/us/stock/forward-pharma-a-s/other-comprehensive-income https://stock.noler.com/us/stock/forward-pharma-a-s/other-current-financial-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/other-current-receivables https://stock.noler.com/us/stock/forward-pharma-a-s/other-finance-cost https://stock.noler.com/us/stock/forward-pharma-a-s/other-finance-income-cost https://stock.noler.com/us/stock/forward-pharma-a-s/other-noncurrent-assets https://stock.noler.com/us/stock/forward-pharma-a-s/other-receivables https://stock.noler.com/us/stock/forward-pharma-a-s/par-value-per-share https://stock.noler.com/us/stock/forward-pharma-a-s/payments-to-acquire-or-redeem-entitys-shares https://stock.noler.com/us/stock/forward-pharma-a-s/prepayments https://stock.noler.com/us/stock/forward-pharma-a-s/proceeds-from-disposal-or-maturity-of-available-for-sale-financial-assets https://stock.noler.com/us/stock/forward-pharma-a-s/proceeds-from-issue-of-ordinary-shares https://stock.noler.com/us/stock/forward-pharma-a-s/proceeds-from-issuing-shares https://stock.noler.com/us/stock/forward-pharma-a-s/professional-fees-expense https://stock.noler.com/us/stock/forward-pharma-a-s/profit-loss https://stock.noler.com/us/stock/forward-pharma-a-s/profit-loss-attributable-to-ordinary-equity-holders-of-parent-entity https://stock.noler.com/us/stock/forward-pharma-a-s/profit-loss-attributable-to-owners-of-parent https://stock.noler.com/us/stock/forward-pharma-a-s/profit-loss-before-tax https://stock.noler.com/us/stock/forward-pharma-a-s/profit-loss-from-operating-activities https://stock.noler.com/us/stock/forward-pharma-a-s/property-plant-and-equipment https://stock.noler.com/us/stock/forward-pharma-a-s/provision-of-guarantees-or-collateral-by-entity-related-party-transactions https://stock.noler.com/us/stock/forward-pharma-a-s/provision-of-guarantees-or-collateral-to-entity-related-party-transactions https://stock.noler.com/us/stock/forward-pharma-a-s/purchase-of-property-plant-and-equipment-classified-as-investing-activities https://stock.noler.com/us/stock/forward-pharma-a-s/reduction-of-issued-capital https://stock.noler.com/us/stock/forward-pharma-a-s/research-and-development https://stock.noler.com/us/stock/forward-pharma-a-s/reserve-of-exchange-differences-on-translation https://stock.noler.com/us/stock/forward-pharma-a-s/reserve-of-gains-and-losses-on-remeasuring-available-for-sale-financial-assets https://stock.noler.com/us/stock/forward-pharma-a-s/retained-earnings https://stock.noler.com/us/stock/forward-pharma-a-s/revenue https://stock.noler.com/us/stock/forward-pharma-a-s/revenue-from-interest https://stock.noler.com/us/stock/forward-pharma-a-s/royalty-expense https://stock.noler.com/us/stock/forward-pharma-a-s/services-received-related-party-transactions https://stock.noler.com/us/stock/forward-pharma-a-s/share-premium https://stock.noler.com/us/stock/forward-pharma-a-s/social-security-contributions https://stock.noler.com/us/stock/forward-pharma-a-s/tax-effect-of-expense-not-deductible-in-determining-taxable-profit-tax-loss https://stock.noler.com/us/stock/forward-pharma-a-s/tax-effect-of-foreign-tax-rates https://stock.noler.com/us/stock/forward-pharma-a-s/tax-expense-income-at-applicable-tax-rate https://stock.noler.com/us/stock/forward-pharma-a-s/termination-benefits-expense https://stock.noler.com/us/stock/forward-pharma-a-s/total-assets https://stock.noler.com/us/stock/forward-pharma-a-s/trade-and-other-current-payables https://stock.noler.com/us/stock/forward-pharma-a-s/transfers-into-level-3-of-fair-value-hierarchy-assets https://stock.noler.com/us/stock/forward-pharma-a-s/transfers-into-level-3-of-fair-value-hierarchy-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/transfers-out-of-level-1-into-level-2-of-fair-value-hierarchy-assets https://stock.noler.com/us/stock/forward-pharma-a-s/transfers-out-of-level-1-into-level-2-of-fair-value-hierarchy-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/transfers-out-of-level-2-into-level-1-of-fair-value-hierarchy-assets https://stock.noler.com/us/stock/forward-pharma-a-s/transfers-out-of-level-2-into-level-1-of-fair-value-hierarchy-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/transfers-out-of-level-3-of-fair-value-hierarchy-assets https://stock.noler.com/us/stock/forward-pharma-a-s/transfers-out-of-level-3-of-fair-value-hierarchy-liabilities https://stock.noler.com/us/stock/forward-pharma-a-s/unused-tax-losses-for-which-no-deferred-tax-asset-recognised https://stock.noler.com/us/stock/forward-pharma-a-s/value-added-tax-receivables https://stock.noler.com/us/stock/forward-pharma-a-s/wages-and-salaries https://stock.noler.com/us/stock/forward-pharma-a-s/weighted-average-shares